Chester County News and Community Website
Ocugen, Inc. (NASDAQ: OCGN), headquartered in Malvern, PA, is a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure blindness diseases. Their breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug – “one to many” and their novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. For more information, visit www.ocugen.com.
MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) has announced the completion of dosing in the Phase 2 portion of its ArMaDa clinical trial for OCU410. This novel multifunctional modifier gene therapy …
Breakthrough Gene Therapy OCU410 Could Save Millions from Vision Loss – Phase 2 Milestone Achieved! Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) has reached a significant milestone in the development of its gene-agnostic therapy, OCU400, as the European Commission has delivered a positive opinion designating it …
Ocugen’s OCU400 Receives ATMP Classification from European Commission, Advancing Retinitis Pigmentosa Treatment Read More MALVERN, PA — Biopharmaceutical company Ocugen, Inc. (NASDAQ: OCGN) has announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for OCU500, a novel …
Ocugen Receives FDA Greenlight for Phase 1 Trial of Mucosal COVID-19 Vaccine Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) this week announced the dosing of the first patient in its Phase 1 clinical trial for OCU200, a potential treatment for diabetic macular edema …
Breakthrough in Sight? Ocugen’s OCU200 Targets Vision Loss for Millions in New Clinical Trial Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) has announced a positive 2-year safety and efficacy update from its Phase 1/2 clinical trial for OCU400, a groundbreaking gene therapy targeting retinitis pigmentosa …
Breakthrough in Vision: Ocugen’s OCU400 Shows Promising 2-Year Results for Retinitis Pigmentosa Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) announced that the Data and Safety Monitoring Board (DSMB) has cleared the continuation of its Phase 1/2 OCU410 ArMaDa clinical trial. This trial is …
Ocugen’s Gene Therapy Trial for Dry AMD Advances Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) has announced that Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder, will present at the Oppenheimer Movers in Rare Disease Summit in New York City …
Ocugen to Present at Oppenheimer Movers in Rare Disease Summit Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) has announced that Dr. Shankar Musunuri, the company’s Chairman, CEO, and Co-Founder, will present at NobleCon20, Noble Capital Markets’ 20th Annual Emerging Growth …
Ocugen, Inc. to Present at NobleCon20 Emerging Growth Equity Conference Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) has received orphan medicinal product designation from the European Medicines Agency (EMA) for OCU410ST, a promising treatment for ABCA4-associated retinopathies including Stargardt disease, …
Ocugen Secures EMA Orphan Designation for OCU410ST, Advancing Stargardt Disease Treatment Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) has unveiled encouraging preliminary data from the Phase 1 portion of its OCU410 ArMaDa clinical trial, aimed at treating geographic atrophy (GA) secondary …
Ocugen Reports Promising Results from OCU410 ArMaDa Trial for Geographic Atrophy Read More